期刊文献+

Linagliptin-Associated Bullous Pemphigoid: The First Case in China

原文传递
导出
摘要 Introduction Bullous pemphigoid(BP)is the most common subepidermal bullous disease and involves an immune response directed against two hemidesmosome components in basal keratinocytes:BP antigen 180(BP180)and BP antigen 230.The major epitope in patients with BP is the noncollagenous 16A(NC16A)domain of BP180.1 BP most commonly occurs in people of advanced age,especially those aged>70 years.The worldwide incidence of BP ranges from 12 to 66 cases per million people per year,and the disease prevalence increases with age.2 Degenerative neurological diseases,psychiatric disorders,and the chronic use of neuroleptics or spironolactone are known independent risk factors for the development of BP.3.
出处 《International Journal of Dermatology and Venereology》 2020年第2期113-115,共3页 国际皮肤性病学杂志(英文)
基金 the National Key Research and Development Program of China Grant(2016YFC0901500) the National Natural Science Foundation of China(81972945) the Milstein Medical Asian American Partnership Foundation and Education Reform Projects of Peking Union Medical College(2016zlgc0106)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部